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Abstract
Background: Canine mammary tumors represent the most common neoplasm in female dogs, and the discovery
of cancer biomarkers and their translation to clinical relevant assays is a key requirement in the war on cancer.
Since the description of the ‘Warburg effect’, the reprogramming of metabolic pathways is considered a hallmark of
pathological changes in cancer cells. In this study, we investigate the expression of two cancer-related metabolic
enzymes, transketolase (TKT) and transketolase-like 1 (TKTL1), involved in the pentose phosphate pathway (PPP), an
alternative metabolic pathway for glucose breakdown that could promote cancer by providing the precursors and
energy required for rapidly growing cells.
Results: TKT and TKTL1 protein expression was investigated by immunohistochemistry in canine normal (N = 6) and
hyperplastic glands (N = 3), as well as in benign (N = 11) and malignant mammary tumors (N = 17). TKT expression
was higher in hyperplastic lesions and in both benign and malignant tumors compared to the normal mammary
gland, while TKTL1 levels were remarkably higher in hyperplastic lesions, simple adenomas and simple carcinomas
than in the normal mammary glands (P < 0.05).
Conclusions: This study reveals that the expression of a key PPP enzyme varies along the evolution of canine
mammary neoplastic lesions, and supports a role of metabolic changes in the development of canine mammary tumors.
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Background
Cancer is the leading cause of death in companion ani-
mals, and mammary tumor, the most common neoplasm
in female dog, represents a serious issue in worldwide
veterinary practice [1, 2]. The etiopathogenesis of canine
mammary tumors (CMT) is still unclear. Despite several
authors reported genetic alterations of oncogenes and
tumor suppressor genes, biological and morphological
heterogeneity of CMTs has challenged veterinary pathol-
ogists since the early days of diagnostic pathology [3, 4].
As in humans, the identification of prognostic markers
represents a major area of investigation in canine mam-
mary cancer and an increasing number of potential
prognostic factors, both clinicopathological and molecu-
lar, have been investigated [2, 4, 5]. However, classical
clinicopathological features are not always sufficient to
predict the biological behavior of CMTs. A few studies
employed proteomic approaches to identify proteins re-
lated to the development and the aggressiveness of ca-
nine mammary tumors [6–9].
In a previous study performed by our group, several
proteins showing an increased abundance in both tumor
and non-tumor bearing canine mammary glands have
been identified. We focused our attention on the enzyme
transketolase (TKT) [9]. TKT, a dimeric protein
* Correspondence: eantuofermo@uniss.it
1Department of Veterinary Medicine, University of Sassari, Via Vienna 2, 07100
Sassari, Italy
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Burrai et al. BMC Veterinary Research  (2017) 13:38 
DOI 10.1186/s12917-017-0961-3
composed of two monomers of about 68 kDa belonging
to the family of transferases, is a thiamin diphosphate-
dependent enzyme that catalyzes a reversible reaction
by the transfer of two carbon atoms from an aldose to a
ketose in the non-oxidative branch of the pentose phos-
phate/hexose monophosphate shunt pathway (PPP)
[10–12]. The PPP pathway has been shown to generate
de novo ribose-5-phosphate (R5P) and NADPH, and
therefore is thought to play a major role in the prolifer-
ation of cancer cells [12, 13]. Constraining TKT activity,
and consequently the PPP, using glycolytic pathway in-
hibitors such as oxythiamine or oxybenfothiamin, was
shown to induce cell apoptosis and to inhibit cell pro-
liferation by the reduction of the major RNA backbone,
R5P, and the main antioxidant NADPH [14–17].
The human genome, in addition to TKT, encodes for
two further TKT-related proteins, termed transketolase-
like 1 (TKTL1) and transketolase-like 2 (TKTL2), which
share 61 and 66% amino acid sequence homology with
TKT, respectively [11]. A marked difference between
TKT and TKTL1 is a deletion of 38 amino acids of the
N-terminal catalytic domain in the latter, suggesting that
TKTL1 is incapable of binding to the thiamine pyro-
phosphate and carrying out the TKT reaction [10, 17].
Furthermore, TKTL1 has been extensively investigated
in cancers, and it has been supposed to be a catalytically
active mutant form of human TKT, through formation
of heterodimers with other TKT isoforms and/or by ac-
tivation of other thiamine derivatives [13, 15].
TKTL1 is overexpressed in a range of human malig-
nancies including breast, colon, ovary, lung, nasophar-
ynx, gastric, renal, cervical, lung and liver cancers, and
increased TKTL1 levels were shown to be associated
with reduced survival for patients with cancers of the
colon, oropharynx, bladder and with oral squamous cell
carcinomas [18–24].
To date, no studies have characterized the protein ex-
pression of TKT and TKTL1 and their potential role in the
onset of canine mammary tumors. Here, we investigate the
expression of TKT and TKTL1 in canine mammary tissues
by immunohistochemistry, exploring hyperplastic lesions
as well as benign and malignant tumors, including simple
and complex types.
Methods
Tissue collection
Thirty-seven fresh mammary samples were obtained
from 35 female dogs that underwent surgery for mam-
mary neoplasia at the Sassari Veterinary Hospital. Dogs
belonged to the following breeds: Mixed breed (20),
Yorkshire Terrier (7), German Shepherd (3) Dachshund
(2), Pinscher (1) Labrador Retriever (1), Poodle (1). The
dog ages ranged from 5 to 15 years (median 11.5 years).
Experiment permission was not required from the
University’s Animal Care Ethics Committee because all
the samples were retrieved from the archive of the path-
ology laboratory and were used for diagnostic purposes.
Immediately after the surgical resection, the specimens
were divided into two aliquots and stored in appropriate
conditions based on the downstream analyses to be
performed.
For histological examination, 10% formalin fixed sam-
ples were dehydrated in graded alcohol, embedded in
paraffin wax, 3 μm-sectioned and stained with haema-
toxylin and eosin (H&E). Mammary samples were classi-
fied according to the World Health Organization criteria
for canine mammary neoplasms [25]. In addition, canine
mammary hyperplastic lesions were further evaluated as
previously described by Antuofermo et al. and Mouser
et al. [26, 27]. Lesions were imaged using Nikon Eclipse
80i and digital computer images were recorded with a
Nikon Ds-fi1 camera.
Western immunoblotting analysis, carried out in order
to validate antibody specificity, employed complemen-
tary tissues from 3 normal mammary glands and 3 sim-
ple tubulopapillary carcinomas that had been snap
frozen upon collection and archived at −80 °C. After
thawing, tissues were included in the Optimal Cutting
Temperature medium (Tissue-Tek, Sakura Finetek,
Torrance, CA, USA) and cut into 10 serial cryosections
(Leica CM 1950, Heidelberg, Germany). Cryostat sec-
tions were histologically evaluated in order to confirm
the presence of neoplastic lesions. Furthermore, HeLa
cells (human fibroblasts derived from uterine cervix car-
cinoma) and ovine milk were retrieved to be used as
positive and negative controls, respectively.
Western immunoblotting
Proteins were extracted by incubating tissue and cell line
samples in SDS-buffer as illustrated elsewhere [28].
Then, about 3 micrograms of each protein extract were
separated by electrophoresis in a polyacrylamide gel
(AnyKD, Bio-Rad, Hercules, CA, USA), blotted onto
nitrocellulose membranes and blocked overnight with
3% bovine serum albumin (BSA) in phosphate-buffered
saline (PBS) plus 0.05% Tween 20. TKT was detected
upon sequential incubation with a mouse monoclonal
anti-TKT primary antibody (1:10000 dilution in PBS plus
3% BSA and 0.05% Tween 20; clone ab112997, Abcam,
Cambridge, UK) and a secondary antibody directed
against mouse immunoglobulin (1:250000 dilution in
PBS plus 1% BSA and 0.05% Tween 20; A9044, HRP,
Sigma-Aldrich, Saint Louis, MO, USA). TKTL1 protein
was detected upon sequential incubation with a rabbit
polyclonal anti-TKTL1 primary antibody (1:2000 dilution
in PBS plus 3% BSA and 0.05% Tween 20; clone LS-4019,
LSBio, Seattle, WA, USA) and a secondary antibody
Burrai et al. BMC Veterinary Research  (2017) 13:38 Page 2 of 9
directed against rabbit immunoglobulin (1:250000 dilu-
tion in PBS plus 1% BSA and 0.05% Tween 20; A9169,
HRP, Sigma-Aldrich). The immunoreactivity was de-
tected using a chemiluminescent peroxidase substrate
(Sigma-Aldrich) and displayed with the VersaDoc Im-
aging System (Bio-Rad).
Immunohistochemistry
To analyze the expression of TKTand TKTL1, histological
sections (3 μm thick) from formalin-fixed, paraffin-
embedded canine mammary tissue were mounted on posi-
tively charged Superfrost slides (Fisher Scientific). Slides
were immersed for 20 min in a 98 °C preheated solution
(WCAP, citrate pH 6, BiOptica, Milan, Italy) that simul-
taneously allows dewaxing, rehydration and antigen
unmasking. Briefly, slides were mounted in a sequenza
chamber (Shandon, Runcorn, UK) and tissues were then
blocked for endogenous peroxidase with a 15 min incuba-
tion in Dako REAL Peroxidase-Blocking Solution (S2023,
Dako, Glostrup, DK), and for nonspecific binding with
2.5% normal horse serum (ImmPRESS reagent kit,
Vector Labs, Burlingame, CA, USA) for 30 min at
room temperature.
Then, sections were incubated overnight at 4 °C with a
mouse monoclonal anti-TKT antibody (clone ab112997,
Abcam) and rabbit polyclonal anti-TKTL1 (clone LS-
B4019, LSBio) at 1:150 and 1:100 dilution, respectively.
Then, sections were incubated for 20 min at room
temperature with an anti-mouse/rabbit secondary
antibody (MP-7500, ImmPRESS reagent kit, Vector
Laboratories, Burlingame, CA, USA). 3,3′-Diaminobenzi-
dine (DAB) (ImmPACT DAB, Vector Laboratories,
Burlingame, CA, USA) was used as chromogen. All wash-
ing steps were performed three times with Tris-buffered
saline (TBS) with 0.1% Tween 20 (BiOptica, Milano, Italy).
Tissues were counterstained with haematoxylin, dehy-
drated and mounted with Eukitt Mounting Medium
(BiOptica, Milan, Italy). A canine testis served as positive
control, while negative controls were carried out by re-
placing the primary antibody with normal mouse or rabbit
serum (ThermoFisher Scientific, Monza, Italy).
Evaluation of immunohistochemical data
The extent of TKT immunopositivity was evaluated con-
sidering the nuclear signal, while the TKTL1 was quanti-
fied by estimating the cytoplasmic immunostaining.
Immunoreactivity was semi-quantitatively scored consid-
ering the number of positive cells in 10 HPF (grade 0:
no positive cells, 1: <10%; 2: 11–30%; 3: 31–60%; 4:>
60%) and the intensity of staining graded as weak (1),
moderate (2), and strong (3). Then, a combined immu-
noreactivity score (IRS), ranging from 1 to 12, was calcu-
lated for each specimen by multiplying the values of
these two categories.
The slides were reviewed independently by two au-
thors (GPB, EA) and a consensus score was obtained for
each case on a multiheaded microscope.
Statistical Analysis
Statistical analysis of immunohistochemical expression
data was carried out using nonparametric Kruskal-Wallis
ANOVA followed by Dunn’s post hoc test. Spearman cor-
relation analysis was performed to evaluate associations of
TKT and TKTL1 protein levels. Data were analyzed with
Stata version 11.2 (StataCorp, 2009), and results were con-
sidered significant when P ≤ 0.05.
Results
Histological classification of lesions
Histologically, the lesions represent a morphologically het-
erogeneous group of samples and were classified as fol-
lows: normal mammary glands (n = 6), ductal hyperplasias
(n = 3), benign tumors (n = 11; 6 simple adenomas and 5
complex adenomas), and carcinomas (n = 17; 11 simple
tubulo-papillary carcinomas and 6 complex carcinomas).
In addition, the 11 simple carcinomas were further char-
acterized as well differentiated (2), moderately differenti-
ated (5) and solid or undifferentiated type according to
Pena and colleagues [29].
Expression of TKT in canine mammary tissues
Antibody reactivity was assessed on three normal mam-
mary glands and three simple tubulo-papillary carcin-
omas (one well-differentiated and two moderately
differentiated) by Western immunoblotting. Reactive
bands were observed at the expected molecular weight
range (around 65 kDa), with different signal intensities,
in normal and in mammary tumor tissues, as well as in
the positive control; no signal was detected in the nega-
tive control (Fig. 1). A band of lower molecular weight
(approx. 50 kDa) was also present in mammary tumor
samples, with different signal intensities, and was absent
from both the positive and the negative control.
Upon immunohistochemical analysis, TKT expression
was found in all tissue types, normal mammary glands
(n = 4/6, 66%; IRS = 0, range 0–4), hyperplastic lesions
(n = 3/3, 100%; IRS = 6, range 1–9), complex adenomas
(n =5/5, 100%; IRS = 4, range 1–9), simple adenomas (n
6/6, 100%; IRS = 5, range 1–9) complex carcinomas (n =
6/6, 100%; IRS = 6, range 1–12) and simple carcinomas
(n = 11/11, 100%; IRS = 1, range 1–9) (Fig. 2) (Additional
file 1). Furthermore, statistical significant differences
were noticed within the different histological lesions
(Additional file 2). In comparison with normal mam-
mary tissue, a significantly increased expression was ob-
served in hyperplastic as well as neoplastic lesions,
suggesting a pivotal role of TKT during the evolution of
mammary carcinogenesis process (P < 0.001).
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In addition, a statistically significant difference be-
tween normal mammary gland and simple carcinomas
(IRS =1) (P < 0.01) was observed, corroborating the data
obtained by mass spectrometry in our previous work,
where TKT was found as differently expressed between
tumor and normal gland both in formalin fixed and
fresh frozen mammary tissues [9].
Moreover, simple carcinomas (IRS = 1) showed IRS
values lower than hyperplastic lesions (IRS = 6) or benign
and malignant tumors, both of simple and complex type,
suggesting a possible existence of an additional pathway
responsible for the onset of more aggressive mammary
neoplasms (P < 0.05). As a partial confirmation of this hy-
pothesis, moderately differentiated carcinomas (grade II)
showed lower IRS values compared to poorly differenti-
ated simple carcinomas (grade III) (P < 0.05).
Expression of TKTL1 in canine mammary tissues
Antibody reactivity against TKTL1 was assessed as
above, on the same 3 normal mammary glands and 3
simple tubulo-papillary carcinomas (1 well-differentiated
and 2 moderately differentiated) by Western immuno-
blotting. Reactive bands were observed for TKTL1 at a
slightly lower molecular weight (approx. 58 kDa) than
TKT, with different signal intensities in normal and in
mammary tumor tissues, as well as in the positive con-
trol; again, no signal was detected in the negative con-
trol. A further reactive band of lower molecular weight
(approx. 53 kDa) was visible in canine mammary tissue
samples, with different signal intensities, and was absent
from the positive and the negative control (Fig. 3).
Immunohistochemically, TKTL1 expression was
found in all tissue types, normal mammary glands (n =
5/6, 83%; IRS = 1, range 0–12), hyperplastic lesions (n =
3/3, 100%; IRS = 12, range 9–12), complex adenomas
(n = 5/5, 100%; IRS = 1, range 0–6), simple adenomas
(n = 6/6, 100%; IRS = 8, range 1–12), complex carcin-
omas (n = 5/6, 83%; IRS = 1, range 0–12) and simple
carcinomas (n = 11/11, 100%; IRS = 3, range 1–12)
(Fig. 4) (Additional file 1).
In particular, hyperplastic lesions (IRS = 12), as well
simple adenomas (IRS = 8) and simple carcinomas
(IRS = 3), showed higher values than the normal
mammary glands (P < 0.001).
Of interest, hyperplastic lesions showed the highest
values of TKTL1 expression when compared to all the
other lesions, suggesting a possible role of the PPP in
the early stage of neoplastic transformation (P = 0.001).
Comparing the expression of TKTL1 among the vari-
ous tumors, it is also worthy of note that the simple type
adenomas and carcinomas tend to show a higher expres-
sion compared to the complex forms, whether they are
benign (IRS = 1) and malignant (IRS = 1), indicating
therefore a predominant role of TKTL1 in the epithelial
cells compared to the myoepithelial component (P <
0.001). This hypothesis is further supported by the
higher TKTL1 expression in simple adenomas than in
complex carcinomas (P < 0.001) (Additional file 3).
Fig. 1 Western immunoblotting verification of anti-transketolase antibody reactivity in canine mammary tissues. Lanes 1–3: normal mammary
glands; lanes 4–6: simple tubulo-papillary carcinomas. Lane 7: reactive control; lane 8: negative control; MW: molecular weight (MW) marker
(MagicMark™ XP Western Protein Standard, Invitrogen). Standard MWs are displayed on the left side
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Significant positive correlations were observed between
TKT and TKTL1 expression in normal mammary gland
(ρ = 0.59, P < 0.05), while a negative correlation was ob-
served for complex adenomas (ρ = −0.39, P = 0.003).
Discussion
Reprogramming of metabolic pathways is considered a
hallmark of pathological changes in cancer cells [30]. Since
the description of the so-called ‘Warburg effect’, it has been
known that neoplastic cells use the anaerobic degradation
of glucose even in the presence of oxygen [31, 32].
This observation kept scientific focus on glycolysis
and highlighted other aspects of glucose metabolism
that could promote cancer by providing the precur-
sors and energy required for a rapidly growing cell,
such as adenosine 5′-triphosphate (ATP) and carbon
intermediates [33].
Noteworthily, an alternative metabolic pathway for
glucose breakdown is the pentose phosphate/hexose
monophosphate shunt pathway [34].
The main purpose of the PPP is to generate R5P,
which is used in the nucleotides synthesis, and NADPH,
that neutralizes reactive oxygen species (ROS) enabling
cancer cells to survive oxidative stress [35]. This can
benefit cancer cells by facilitating cell proliferation,
tumor invasion and resistance to apoptosis, which in
turn promotes tumor invasion [36].
Thus, in this study, we sought to analyze by immuno-
histochemistry the expression of TKT, a key enzyme in
the non-oxidative part of the PPP, and TKTL1, a TKT
isoform frequently reported in human tumor related
pathways, in a retrospective patient cohort with invasive
canine mammary tumor as well as in normal and hyper-
plastic mammary glands. As a result, the expression of
TKT was observed in all examined mammary tissues.
Fig. 2 Transketolase immunohistochemical expression in canine mammary glands. Nuclear expression of TKT in epithelial cells of normal
mammary gland (IRS = 1) (a), hyperplastic mammary gland (IRS = 9) (b), complex adenoma (IRS = 4) (c), simple adenoma (IRS = 6) (d), complex
carcinoma (IRS = 4) (e) and simple carcinoma (IRS = 2) (f)
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Furthermore, the increased protein expression in hyper-
plastic lesions and in both benign and malignant tumors
compared to normal mammary gland suggests a significant
involvement of the PPP and, consequently a role of TKT
during the canine mammary carcinogenesis process. The
increased expression of TKT found in mammary tumors
and in hyperplastic lesions of the dog appears to be sub-
stantially in agreement with those reported in recent stud-
ies carried out in human and veterinary medicine, in which
there was an increased expression of TKT in cancer tissues
and in progestin-induced canine mammary hyperplasia
compared to non-tumor tissues, respectively [12, 36, 37].
In addition, our results lead to hypothesize that a
pathway that synthesizes antioxidants, the PPP, is ne-
cessary to tumor development, particularly in hyper-
plastic lesions where TKT is an up regulated gene
and reaches the highest protein expression values,
thus confirming what has been described in the
mouse mammary tumor model by Lu and colleagues
[36, 38]. In fact, as elegantly proposed by Gatenby
and Gilles in 2004, hyperplastic lesions are exposed
to a hypoxic environment and acquire the glycolytic
phenotype with the production of hydrogen ions (H+);
this leads to the consequent acidification of the extra-
cellular space, resulting in cellular toxicity due the
increase of ROS [39]. Thus, an increase of PPP
down-streaming molecules, such as NADHP, is
necessary to counteract and mitigate oxidative stress,
especially in hyperplastic lesions.
In this study, simple carcinomas showed a lower ex-
pression of TKT when compared to the others lesions,
with a significant reduction of the enzyme in the most
undifferentiated forms (i.e. simple carcinoma grade III).
The underexpression trend of TKT in the more aggres-
sive neoplasm suggests that probably a further molecular
pathway exists that limits or inhibits the protein expres-
sion in the most aggressive and life-threatening mam-
mary neoplastic histotype. For example, it was revealed
that the tumor suppressor p53, often expressed in canine
carcinomas, can inhibit the PPP by binding to glucose-6-
phosphate dehydrogenase (G6PD), the rate-limiting
enzyme in the oxidative branch of the PPP, which ul-
timately results in decreased transketolase expression
[40, 41]. Moreover, additional and more focused stud-
ies are needed in order to confirm this hypothesis.
As a partial confirmation of the validity of our results
and of the important role played by the TKT in the car-
cinogenic process, several studies report that the use of
transketolase competitive inhibitors, such as oxythia-
mine, in experimental models significantly reduces the
tumor cell proliferation rate [14, 16, 42].
Compelling evidence has proved that TKTL1 is a can-
cer related molecule and that it plays a key role in the
onset of different neoplastic disease. Its overexpression
Fig. 3 Western immunoblotting verification of anti-transketolase-like-1 antibody reactivity in canine mammary tissues. Lanes 1–3: normal mam-
mary glands; lanes 4–6: simple tubulo-papillary carcinomas. Lane 7: reactive control; lane 8: negative control; MW: molecular weight (MW) marker
(MagicMark™ XP Western Protein Standard, Invitrogen). Standard MWs are displayed on the left side
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predicts poor patient survival, tumor recurrence and
resistance to chemo and radiation therapy in many
cancers [18–24].
In our work, TKTL1 was expressed in most of the hy-
perplastic and neoplastic lesions and in 83% of non-
neoplastic mammary tissue. Furthermore, the statistical
analysis of different histological types showed an in-
creased TKTL1 expression in hyperplastic lesions and
in both benign and malignant simple tumors, in
agreement with other reports in women breast cancer
[18, 43]. However, in contrast to what described by
these authors, TKTL1 expression in mammary tissues
of the dog showed higher values in hyperplastic lesions
and a reduction of the immunoreactivity as the degree
of malignancy increased. This indicates that the protein
could play a crucial role in the stepwise progression
from early hyperplastic lesions to fully malignant CMT.
In fact, hyperplastic lesions have been considered as
risk factors for subsequent development of invasive
mammary cancer both in human and in canine species
[26, 44, 45]. In this perspective, we might speculate that
the selective block of TKTL1 through the targeting of
PPP metabolic pathway could limit neoplastic develop-
ment in its early stages represented by hyperplastic and
benign tumors, arresting tumor progression in its
“primum movens”.
In addition, TKTL1 was more expressed in simple ca-
nine neoplasms, both benign and malignant, when com-
pared to complex types, suggesting a predominant role of
TKTL1 in epithelial cells vs the myoepithelial component.
Moreover, to our knowledge, no studies have investigated
the role of TKT or TKTL1 in myoepithelial cells, both in
Fig. 4 Transketolase like-1 immunohistochemical expression in canine mammary glands. Cytoplasmic expression in epithelial cells of normal
mammary gland (IRS = 1) (a), hyperplastic mammary gland (IRS = 12) (b), complex adenoma (IRS = 1) (c), simple adenoma (IRS = 8) (d), complex
carcinoma (IRS = 4) (e) and simple carcinoma (IRS = 6) (f)
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human and canine tumors, and consequently, definitive
and conclusive hypothesis cannot be drawn.
Conclusions
In conclusion, this is the first study investigating the ex-
pression of TKT and TKT-like enzymes in canine mam-
mary tumors and hyperplastic lesions. We observed
increased expression of TKT and TKTL1 in the pro-
posed multistep carcinogenesis of CMT, thus indicating
that PPP is a cancer metabolism-related pathway also in
canine mammary tumors. TKTL1 has recently been used
as a biomarker in a blood test based on the epitope de-
tection in monocytes (EDIM) technology, allowing for
the non-invasive detection of neoplasia and tumor recur-
rence, and thereby it has been proposed as a therapeutic
target [42]. Similar efforts to identify important meta-
bolic changes during canine mammary cancer progres-
sion hold the potential for providing putative diagnostic
and prognostic biomarkers, as well as new therapeutic
targets, also in canine species.
Additional files
Additional file 1: Immunohistochemical evaluation of TKT and TKTL1.
Immunoreactivity scores (IRS) of normal mammary glands (n = 6), ductal
hyperplasias (n = 3), benign tumors (n = 11), and carcinomas (n = 17),
considering the number and the stain intensity of positive cells per high
power field (HPF). (XLSX 18 kb)
Additional file 2: Graphical representation (box-plot) of TKT
immunohistochemical evaluation. Immunoreactivity scores (IRS) of
normal mammary glands (n = 6), ductal hyperplasias (n = 3), benign
tumors (n = 11) and carcinomas (n = 17), with statistical differences
between lesions. Different letters (a, b, c, d) indicate significant
differences (P < 0.05), red line (median values), Kruskal-Wallis ANOVA
followed by Dunn’s post hoc test. (TIF 1566 kb)
Additional file 3: Graphical representation (box-plot) of TKTL1
immunohistochemical evaluation. Immunoreactivity scores (IRS) of
normal mammary glands (n = 6), ductal hyperplasias (n = 3), benign
tumors (n = 11) and carcinomas (n = 17), with statistical differences
between lesions. Different letters (a, b, c, d) indicate significant
differences (P < 0.05), red line (median values), Kruskal-Wallis ANOVA
followed by Dunn’s post hoc test. (TIF 970 kb)
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